{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:15:28Z","timestamp":1794892528979,"version":"4.9.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Preexisting autoimmune disease affects between 10% and 30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in patients with MDS with and without autoimmune disease show discordant results. Using the Surveillance, Epidemiology, and End Results Medicare database, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 and 2017 and claim algorithms used to identify autoimmune disease, demographic characteristics, comorbidity scores, MDS histology, transfusion burden, treatment with hypomethylating agents, and hematopoietic stem cell transplantation. Cox regression models estimated the impact on survival, and competing-risk regression models defined the effect on leukemic transformation. We analyzed 15\u2009277 patients with MDS, including 2442 (16%) with preexisting autoimmune disease. The epidemiologic profile was distinctive in cases with preexisting autoimmunity, who were younger, were predominantly female, and had higher transfusion burden without difference in MDS histologic distribution. Autoimmune disease was associated with 11% decreased risk of death (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.85-0.94; P\u00a0&amp;lt; .001). The effect on risk of leukemic transformation differed based on MDS histology. In low-risk MDS histologies, autoimmunity was associated with a 1.9-fold increased risk of leukemia (HR, 1.87; 95%\u00a0CI, 1.17-2.99; P\u00a0= .008), whereas no significant effect was seen in other groups. These results suggest that autoimmune disease affects survival in MDS and is associated with decreased mortality. The survival effect was evident in low-risk histologies despite higher risk of progression to leukemia. This could represent inflammation-driven hematopoiesis, simultaneously favoring less aggressive phenotypes and clonal expansion, which warrants further investigation.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023011050","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:24:39Z","timestamp":1695241479000},"page":"6913-6922","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2165","authenticated-orcid":false,"given":"Diego","family":"Adrianzen-Herrera","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-4105","authenticated-orcid":false,"given":"Andrew D.","family":"Sparks","sequence":"additional","affiliation":[{"name":"2Biomedical Statistics Research Core, University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2740-9386","authenticated-orcid":false,"given":"Rohit","family":"Singh","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alejos-Castillo","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshee","family":"Batra","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Glushakow-Smith","sequence":"additional","affiliation":[{"name":"3Department of Oncology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kith","family":"Pradhan","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[{"name":"3Department of Oncology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8824-4410","authenticated-orcid":false,"given":"Neil A.","family":"Zakai","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT"},{"name":"5Department of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"8","key":"2023112812510252100_bib1","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2023112812510252100_bib2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"2023112812510252100_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2017.12.013","article-title":"Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies","volume":"122","author":"Wang","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2023112812510252100_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ganan-Gomez","year":"2015","journal-title":"Leukemia"},{"issue":"27","key":"2023112812510252100_bib5","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023112812510252100_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023112812510252100_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/ijms17060944","article-title":"Immune mechanisms in myelodysplastic syndrome","volume":"17","author":"Glenthoj","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2023112812510252100_bib8","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"2023112812510252100_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"55","author":"Mekinian","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2023112812510252100_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"issue":"7","key":"2023112812510252100_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023112812510252100_bib12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-018-3472-9","article-title":"Autoimmune manifestations associated with myelodysplastic syndromes","volume":"97","author":"Grignano","year":"2018","journal-title":"Ann Hematol"},{"issue":"8","key":"2023112812510252100_bib13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00277-018-3302-0","article-title":"Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes","volume":"97","author":"Montoro","year":"2018","journal-title":"Ann Hematol"},{"issue":"13","key":"2023112812510252100_bib14","doi-asserted-by":"crossref","first-page":"e3091","DOI":"10.1097\/MD.0000000000003091","article-title":"Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective cohort study","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2023112812510252100_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2018.07.009","article-title":"Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review","volume":"18","author":"Seguier","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2023112812510252100_bib16","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"issue":"55","key":"2023112812510252100_bib17","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"8 suppl","key":"2023112812510252100_bib18","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"2023112812510252100_bib19","author":"World Health Organization","year":"2013","edition":"Third Edition"},{"issue":"4","key":"2023112812510252100_bib20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bjh.16222","article-title":"Autoimmune conditions and primary central nervous system lymphoma risk among older adults","volume":"188","author":"Mahale","year":"2020","journal-title":"Br J Haematol"},{"key":"2023112812510252100_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2017.11.024","article-title":"How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis","volume":"115","author":"Khan","year":"2018","journal-title":"Lung Cancer"},{"issue":"11","key":"2023112812510252100_bib22","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/1055-9965.EPI-21-0125","article-title":"Tumor necrosis factor inhibitors and the risk of cancer among older americans with rheumatoid arthritis","volume":"30","author":"D'Arcy","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"2023112812510252100_bib23","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2017010165","article-title":"Risk and timing of cardiovascular death among patients with myelodysplastic syndromes","volume":"1","author":"Brunner","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"2023112812510252100_bib24","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41375-019-0673-8","article-title":"Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: a SEER-medicare analysis","volume":"34","author":"Adrianzen Herrera","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2023112812510252100_bib25","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/j.clml.2020.10.013","article-title":"Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis","volume":"21","author":"Corman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2023112812510252100_bib26","first-page":"234","article-title":"Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis","volume":"24","author":"Stein","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"2023112812510252100_bib27","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/10428194.2019.1703970","article-title":"Hypomethylating agent (HMA) therapy use and survival in older adults with refractory anemia with excess blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study(dagger)","volume":"61","author":"Davidoff","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023112812510252100_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.33256","article-title":"Rural-urban and racial\/ethnic trends and disparities in early-onset and average-onset colorectal cancer","volume":"127","author":"Zahnd","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"2023112812510252100_bib29","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1055-9965.EPI-19-0021","article-title":"Providing higher resolution indicators of rurality in the Surveillance, Epidemiology, and End Results (SEER) Database: implications for patient privacy and research","volume":"28","author":"Moss","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"2023112812510252100_bib30","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"11","key":"2023112812510252100_bib31","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1080\/1042819021000016186","article-title":"Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Saif","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023112812510252100_bib32","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/acr.20504","article-title":"Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study","volume":"63","author":"de Hollanda","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2023112812510252100_bib33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.canep.2014.08.003","article-title":"Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database","volume":"38","author":"Wilson","year":"2014","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"2023112812510252100_bib34","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/ijc.34140","article-title":"Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States","volume":"151","author":"Wang","year":"2022","journal-title":"Int J Cancer"},{"issue":"7","key":"2023112812510252100_bib35","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(22)00138-7","article-title":"Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?","volume":"9","author":"Hochman","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10","key":"2023112812510252100_bib36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00018-015-1846-x","article-title":"The inflammatory microenvironment in MDS","volume":"72","author":"Yang","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2023112812510252100_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.hoc.2010.02.008","article-title":"Innate immune signaling in the myelodysplastic syndromes","volume":"24","author":"Starczynowski","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"2023112812510252100_bib38","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2023112812510252100_bib39","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2023112812510252100_bib40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/cncr.29945","article-title":"Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes","volume":"122","author":"Zeidan","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"2023112812510252100_bib41","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.leukres.2014.09.011","article-title":"Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS)","volume":"38","author":"Uno","year":"2014","journal-title":"Leuk Res"},{"issue":"26","key":"2023112812510252100_bib42","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023112812510252100_bib43","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6913\/2111117\/blooda_adv-2023-011050-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6913\/2111117\/blooda_adv-2023-011050-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:51:54Z","timestamp":1701175914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/6913\/497971\/Impact-of-preexisting-autoimmune-disease-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":43,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011050","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}